[go: up one dir, main page]

CA2234936A1 - Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine - Google Patents

Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine Download PDF

Info

Publication number
CA2234936A1
CA2234936A1 CA002234936A CA2234936A CA2234936A1 CA 2234936 A1 CA2234936 A1 CA 2234936A1 CA 002234936 A CA002234936 A CA 002234936A CA 2234936 A CA2234936 A CA 2234936A CA 2234936 A1 CA2234936 A1 CA 2234936A1
Authority
CA
Canada
Prior art keywords
composition
bowel disease
inflammatory bowel
ibd
acetylglucosamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002234936A
Other languages
French (fr)
Other versions
CA2234936C (en
Inventor
Simon Murch
Ian W. French
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLUCOGENICS PHARMACEUTICALS Inc
Original Assignee
GLUCOGENICS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLUCOGENICS PHARMACEUTICALS Inc filed Critical GLUCOGENICS PHARMACEUTICALS Inc
Priority to CA002234936A priority Critical patent/CA2234936C/en
Priority to US09/261,194 priority patent/US6046179A/en
Priority to AU27092/99A priority patent/AU2709299A/en
Priority to JP2000544333A priority patent/JP2002512195A/en
Priority to EP99907220A priority patent/EP1071432A1/en
Priority to CZ20003846A priority patent/CZ20003846A3/en
Priority to PCT/CA1999/000218 priority patent/WO1999053929A1/en
Priority to IL13907299A priority patent/IL139072A0/en
Priority to PL99343634A priority patent/PL343634A1/en
Priority to HU0101514A priority patent/HUP0101514A3/en
Publication of CA2234936A1 publication Critical patent/CA2234936A1/en
Priority to NO20005223A priority patent/NO20005223L/en
Application granted granted Critical
Publication of CA2234936C publication Critical patent/CA2234936C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to a novel composition and a novel method of treating inflammatory bowel disease (IBD). More particularly, this invention pertains to a novel composition containing N-acetyl- glucosamine (NAG) as an active IBD treating agent and a pharmacologi- cally suitable carrier, and a method of administering the composition to the colon to treat IBD in a person afflicted with IBD. A composition for treating inflammatory bowel disease in a patient suffering from inflamma- tory bowel disease comprising: (a) a therapeutic amount of N-acetyl- glucosamine; and (b) a pharmacologically acceptable carrier, adapted to be administered colonically to said patient.
CA002234936A 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine Expired - Fee Related CA2234936C (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (en) 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
US09/261,194 US6046179A (en) 1998-04-17 1999-03-03 Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
HU0101514A HUP0101514A3 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
EP99907220A EP1071432A1 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
CZ20003846A CZ20003846A3 (en) 1998-04-17 1999-03-12 Composition for treating inflammatory disease of intestines by dosage of N-acetylglucosamine into large intestine
PCT/CA1999/000218 WO1999053929A1 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
AU27092/99A AU2709299A (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
PL99343634A PL343634A1 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
JP2000544333A JP2002512195A (en) 1998-04-17 1999-03-12 Composition for inflammatory bowel disease by colonic administration of N-acetylglucosamine and treatment therefor
IL13907299A IL139072A0 (en) 1998-04-17 1999-03-12 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
NO20005223A NO20005223L (en) 1998-04-17 2000-10-17 Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002234936A CA2234936C (en) 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine

Publications (2)

Publication Number Publication Date
CA2234936A1 true CA2234936A1 (en) 1999-10-17
CA2234936C CA2234936C (en) 2004-06-29

Family

ID=4162337

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234936A Expired - Fee Related CA2234936C (en) 1998-04-17 1998-04-17 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine

Country Status (8)

Country Link
EP (1) EP1071432A1 (en)
JP (1) JP2002512195A (en)
CA (1) CA2234936C (en)
CZ (1) CZ20003846A3 (en)
HU (1) HUP0101514A3 (en)
IL (1) IL139072A0 (en)
NO (1) NO20005223L (en)
PL (1) PL343634A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2621018T3 (en) 2007-02-19 2017-06-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
KR101098581B1 (en) * 2009-01-09 2011-12-26 서울대학교산학협력단 Composition for Improving Inflammatory Disorder Using ABH Antigen
CN103108638B (en) 2010-04-15 2016-11-09 海洋聚合物技术公司 Antibacterial application of poly-N-acetylglucosamine nanofibers
WO2012142581A1 (en) 2011-04-15 2012-10-18 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acety glucosamine nanofibers
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
HUE049247T2 (en) * 2014-11-26 2020-09-28 Evonik Operations Gmbh Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
KR102104507B1 (en) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same

Also Published As

Publication number Publication date
IL139072A0 (en) 2001-11-25
JP2002512195A (en) 2002-04-23
HUP0101514A3 (en) 2003-07-28
NO20005223L (en) 2000-11-20
NO20005223D0 (en) 2000-10-17
EP1071432A1 (en) 2001-01-31
CA2234936C (en) 2004-06-29
PL343634A1 (en) 2001-08-27
HUP0101514A2 (en) 2001-11-28
CZ20003846A3 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
PT1409006E (en) Monodispersed mixtures and methods of treating diabetes
CA2311356A1 (en) Method for treating alzheimer's disease
HRP920632B1 (en) Oral composition for the treatment of inflammatory bowel deseases
WO2003024387A3 (en) Method and pharmaceutical composition for treating inflammation
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2289717A1 (en) Novel therapy for constipation
NO954996D0 (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IL133585A0 (en) Soluble prodrugs of paclitaxel
EP0693281A3 (en) Pharmaceutical formulations containing fluoxetine
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
CA2186673A1 (en) The use of fatty acids in the treatment of huntington's chorea
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
MXPA02002681A (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer.
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
CA2290482A1 (en) Fructan containing composition for the prevention and treatment of colon cancer
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
WO2003049667A3 (en) The method of treating cancer
AU2003290015A1 (en) Mastitis treatment

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130417